@inproceedings{inproceedings, title  = {{Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial}},

 url = {{}},

 year = {{2021}},

 month = {{1}},

 author = {{Paller A and Cork MJ and Marcoux D and Zhang H and Chuang C and Zhang A and Chao J}},

 volume = {{141}},

 journal = {{JOURNAL OF INVESTIGATIVE DERMATOLOGY}},

 issue = {{5}},

 pages = {{S84-S84}},

 note = {{Accessed on 2024/12/22}}}